0.36
-5.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tempest Therapeutics
From its filings with the US Securities and Exchange Commission
Tempest Therapeutics is based in Brisbane, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TPST. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2017, it reported revenue of $295,000.
We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells (“CAR-T”) product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen (“BCMA”) CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma (“rrMM”).
Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma (“HCC”). Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis (“FAP”), with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute (“NCI”) and conducted through the Cancer Prevention Clinical Trials Network (“CP-CTNet”), enabling advancement with limited internal capital deployment.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Oct 2012
- Employees
- 19
- Website
- tempesttx.com ↗
- Head office
- 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Stephen BradyChairman of the Board, since 2021$1.9m
- Dr. Matthew AngelPresident, Chief Executive Officer, Director, since 2026
- Mr. Nicholas MaestasChief Financial Officer, Head - Corporate Strategy, Corporate Secretary$622,095
- Dr. Samuel WhitingExecutive Vice President, Chief Medical Officer$1.1m
- Ms. Christine PellizzariIndependent Director$95,403
- Mr. Michael RaabIndependent Director$145,903
- Dr. Ronit SimantovIndependent Director$88,403
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 21
- Environment
- 24
- Social
- 14
- Governance
- 26
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical-stage biotechnology company with two active drug programs in Phase I/II trials.
- TPST-1120 targets PPARa for solid tumors with global Phase Ib/II trials in HCC.
- TPST-1495 is a dual EP2/EP4 antagonist in Phase I trials for solid tumors.
Weaknesses
- 19 full-time employees indicate limited workforce capacity for development.
- Headquartered in Brisbane California, a small city with limited biotech infrastructure.
- IPO in 2012 suggests long development timeline without significant revenue.
Opportunities
- Expanding clinical trials for TPST-1120 in combination with atezolizumab and bevacizumab globally.
- Growing demand for targeted cancer therapies in the Health Care sector.
- Potential partnerships with larger biotech firms for drug development.
Threats
- Competition from established biotech companies in the Health Care sector.
- Regulatory delays in clinical trials for cancer drugs.
- Dependence on successful Phase I/II trial results for future funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.